Physician profile
Stephen P Lordon
NPI 1275532020
$322.42
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $69.93 | 2019 | |
| Assertio Therapeutics, INC. | $50.49 | 2019 | |
| Pfizer INC. | $39.92 | 2019 | |
| Scilex Pharmaceuticals INC. | $34.75 | 2019 | |
| Zyla Life Sciences, INC. | $30.44 | 2019 | |
| Amniox Medical, INC. | $21.65 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.50 | 2019 | |
| Sentynl Therapeutics, INC. | $17.51 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.14 | 2019 | |
| Lilly USA, LLC | $11.56 | 2019 | |
| Fidia Pharma USA INC. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.